ORGANOMANGANESE REAGENTS IN ORGANIC SYNTHESIS
有机合成中的有机锰试剂
基本信息
- 批准号:3297024
- 负责人:
- 金额:$ 14.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1989
- 资助国家:美国
- 起止时间:1989-04-01 至 1992-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This research proposal describes a series of experiments designed to probe
the ability of organomanganese pentacarbonyl complexes to serve as reagents
for the synthesis of structurally complex organic substances. The proposal
is comprised of three sections. In the first, methodological studies are
outlined. These include determination of the scope and limitation of the
sequential insertion reaction, novel methodology for the preparation of
highly functionalized manganese complexes, in particular glycosylmanganese
complexes, and intramolecular variants of the sequential insertion
reaction.
The second section of the proposal describes the application of
organomanganese reagents to the total synthesis of C-glycosyl substances
tiazofurin (NSC-286193), selenazofurin, and pyrazofurin in optically active
form. Tiazofurin and selenazofurin are synthetic C-nucleosides which
possess potent antiviral and antitumor activity. For instance, both
substances exhibit activity against Lewis lung carcinoma and L1210 and P388
leukemias in vivo.
Pyrazofurin is a C-nucleoside isolated from Streptomyces candidus which has
antitumor and broad spectrum antiviral activity. Pyrazofurin suppresses
the replication of vaccinia, herpes simplex, measles, rhino and influenza
viruses, and Friend and Rauscher leukemia virus in mice. Cultured Novikoff
rat hepatome cells, HeLa cells and mouse L cells are also sensitive to
pyrazofurin.
The final section of the proposal describes preliminary studies of the
utilization of organomanganese pentacarbonyl complexes for the synthesis of
systems found in natural products such as C-arylated glycosyl compounds and
polyether systems. The compounds synthesized during this investigation
will serve as model compounds for the total synthesis of vineomycin B,
pluramycin, chrysomycin B, lasolocid and monensin.
这项研究计划描述了一系列旨在探索
有机锰五羰基配合物作为试剂的能力
用于合成结构复杂的有机物质。 该提案
由三部分组成。 首先,方法论研究是
概述。 其中包括确定《公约》的范围和限制,
序贯插入反应,新的制备方法,
高度官能化的锰络合物,特别是糖基锰
复合物,以及顺序插入的分子内变体
反应
提案的第二部分介绍了
有机锰试剂在碳糖基物质全合成中的应用
噻唑弗林(NSC-286193),硒唑弗林,并在光学活性
form. 硫唑弗林和硒唑弗林是合成的C-核苷,
具有很强的抗病毒和抗肿瘤活性。 比方说都
对刘易斯肺癌和L 1210和P 388显示活性物质
体内白血病
吡唑呋啶是从白色链霉菌中分离的C-核苷,
抗肿瘤和广谱抗病毒活性。 吡唑弗林抑制
牛痘、单纯疱疹、麻疹、犀牛和流感的复制
病毒,以及小鼠中的Friend和Rauscher白血病病毒。 文化Novikoff
大鼠肝细胞、HeLa细胞和小鼠L细胞也对
阿佐弗林。
提案的最后一节介绍了对
利用有机锰五羰基配合物合成
天然产物中发现的系统,如C-芳基化糖基化合物,
聚醚体系 本研究中合成的化合物
将作为全合成长春霉素B的模型化合物,
普朗霉素、金霉素B、拉索罗菌素和莫能菌素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILIP Ridley DESHONG其他文献
PHILIP Ridley DESHONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILIP Ridley DESHONG', 18)}}的其他基金
An LC-TOF for Accurate Molecular Mass Determinations
用于精确分子量测定的 LC-TOF
- 批准号:
6731560 - 财政年份:2004
- 资助金额:
$ 14.27万 - 项目类别:
AN LC-TOF FOR ACCURATE MOLECULAR MASS DETERMINATIONS: BIOCHEMISTRY
用于精确分子质量测定的 LC-TOF:生物化学
- 批准号:
6973611 - 财政年份:2004
- 资助金额:
$ 14.27万 - 项目类别:
SILOXANE COUPLINGS AND NATURAL PRODUCT SYNTHESIS
硅氧烷偶联剂和天然产物合成
- 批准号:
6377292 - 财政年份:1999
- 资助金额:
$ 14.27万 - 项目类别:
SILOXANE COUPLINGS AND NATURAL PRODUCT SYNTHESIS
硅氧烷偶联剂和天然产物合成
- 批准号:
6173577 - 财政年份:1999
- 资助金额:
$ 14.27万 - 项目类别:
SILOXANE COUPLINGS AND NATURAL PRODUCT SYNTHESIS
硅氧烷偶联剂和天然产物合成
- 批准号:
2881541 - 财政年份:1999
- 资助金额:
$ 14.27万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 14.27万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 14.27万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 14.27万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 14.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 14.27万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 14.27万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 14.27万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 14.27万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 14.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 14.27万 - 项目类别:














{{item.name}}会员




